Browse > Article
http://dx.doi.org/10.4014/jmb.1010.10043

Purification of Capsular Polysaccharide Produced by Streptococcus pneumoniae Serotype 19A  

Jung, Seung-Jin (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University)
Seo, Eun-Seong (School of Biological Sciences and Technology, Chonnam National University)
Yun, Sang-Il (School of Biological Sciences and Technology, Chonnam National University)
Minh, Bui Nguyet (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University)
Jin, Sheng-De (School of Biological Sciences and Technology, Chonnam National University)
Ryu, Hwa-Ja (School of Biological Sciences and Technology, Chonnam National University)
Kim, Do-Man (Interdisciplinary Program of Graduate School for Bioenergy and Biomaterials, Chonnam National University)
Publication Information
Journal of Microbiology and Biotechnology / v.21, no.7, 2011 , pp. 734-738 More about this Journal
Abstract
Streptococcus pneumoniae is a major cause of invasive infection in young infants and older adults. There are currently 90 capsular serotypes identified and 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F) are responsible for about 90% of invasive disease. Among the more than 90 different S. pneumoniae serotypes, serotype 19A is globally very prevalent. A simplified purification procedure including adjustment of cell lysate pH to 4.5, fractionation with 50. 80% ethanol, and dialysis rendered capsular polysaccharide (CPS) in a yield of $31.32{\pm}3.11$ mg from 1 l culture (75% recovery after lyses). The product contained only 69.6 ${\mu}g$ of protein (99.78% purity) and 0.8mg (sum of the precipitants from 50~60%, 60~70%, and 70~80%) of nucleic acid (97.45% purity). The purified CPS was conjugated with bovine serum albumin; the product size ranged from 100 to 180 kDa.
Keywords
Capsular polysaccharide; conjugation; Streptococcus pneumoniae type 19A; purification;
Citations & Related Records

Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
  • Reference
1 Alonso de Velasco, E., A. F. Verheul, G. H. Veeneman, L. J. Gomes, J. H. van Boom, J. Verhoef, and H. Snippe. 1993. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide. Vaccine 11: 1429-1436.   DOI   ScienceOn
2 Arnold, F. 1998. Alcohol-free pneumococcal polysaccharide purification process. US Patent 5714354.
3 World Health Organisation. 2000. Recommendations for the production and control of Haemophilus influenzae type b conjugate vaccines. WHO Tech. Rep. Ser. 897: 27-56.
4 World Health Organization (2005). Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser. 927: 64-98.
5 World Health Organization. 2004. Recommendations for the production and control of meningococcal group C conjugate vaccines. WHO Tech. Rep. Ser. 924: 102-128.
6 Yuan, Y. T., M. G. Ruppen, W. M. Sun, L. S. Chu, J. U. N. Simpson, J. C. O. H. Patch, J. K. V. C. Moran, and P. N. C. Fink. 2008. Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharide. US Patent WO/2008/118752.
7 Katzenellenbogen, E. and H. J. Jennings. 1983. Structural determination of the capsular polysaccharide of Streptococcus pneumoniae type 19A. Carbohydr. Res. 124: 235-245.   DOI   ScienceOn
8 Choi, E. H., S. H. Kim, B. W. Eun, S. J. Kim, N. H. Kim, J. Lee, and H. J. Lee. 2008. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14: 275-281.   DOI
9 Dagan, R., M. Isaachson, R. Lang, J. Karpuch, C. Block, and J. Amir. 1994. Epidemiology of pediatric meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in Israel: A 3-year nationwide prospective study. J. Infect. Dis. 169: 912-916.   DOI   ScienceOn
10 Ghebregzabher, M., S. Rufini, B. Monaldi, and M. Lato. 1976. Thin-layer chromatography of carbohydrates. J. Chromatogr. 127: 133-162.   DOI   ScienceOn
11 Musher, D. M. 1992. Infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14: 801-807.   DOI   ScienceOn
12 Myers, C. and A. Gervaix. 2007. Streptococcus pneumoniae bacteraemia in children. Int. J. Antimicrob. Agents 30S: S24- S28.
13 Pelton, S. I., H. Huot, J. A. Finkelstein, C. J. Bishop, K. K. Hsu, and J. Kellenberg. 2007. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26: 468-472.   DOI   ScienceOn
14 Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.   DOI   ScienceOn
15 Skov-Sorensen, U. B., J. Blom, A. Birch-Andersen, and J. Henrichsen. 1988. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci. Infect. Immun. 56: 1890-1896.
16 Avery, O. T. and R. Dubos. 1931. The protective action of a specific enzyme against type Iii pneumococcus infection in mice. J. Exp. Med. 54: 73-89.   DOI
17 Bednar, B. and J. P. Hennessey. 1993. Molecular size analysis of capsular polysaccharide preparations from Streptococcus pneumoniae. Carbohydr. Res. 243: 115-130.   DOI   ScienceOn
18 Brian, B., T. Lee, J. A. Lotvin, M. E. Ruppen, and P. F. Charbonneau. 2006. Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation. US Patent 0228381.
19 Bruyn, G. A. and R. van Furth. 1991. Pneumococcal polysaccharide vaccines: Indications, efficacy and recommendations. Eur. J. Clin. Microbiol. Infect. Dis. 10: 897-910.   DOI   ScienceOn
20 Cano, F. J. S. V., J. S. C. O. Kuo, and M. V. R. V. Querry. 1980. Purification of pneumococcal capsular polysaccharides. US Patent 4242501.